What's new

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 34, Status: Authorised

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 34, Status: Authorised

Feb 20, 2025 - 09:58
 0
Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 34, Status: Authorised
Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 34, Status: Authorised
Read More

Tags:

Previous Article

Dacia developing £15k city car for Europe

Next Article

The #1 Factor That Leads to Home Price Growth (You CAN Predict This)

Related Posts

Human medicines European public assessment report (EPAR): Skytrofa (previously Lonapegsomatropin Ascendis Pharma), lonapegsomatropin, Date of authorisation: 11/01/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 12, 2025  0

PSUSA/00010605/202407

PSUSA/00010605/202407

Feb 13, 2025  0

Summary of opinion: Kalydeco, 27/02/2025 Positive

Summary of opinion: Kalydeco, 27/02/2025 Positive

Feb 28, 2025  0